welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

UT researcher, with CureDuchenne support, launches company to treat DMD using CRISPR/Cas9 technology

Eric Olson, a molecular biologist, has spent more than half his life in the lab. Now, the 62-year-old University of Texas researcher and distinguished professor is a businessman as well.

Olson, director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine in Dallas, has teamed up with the nonprofit group CureDuchenne — through its investment arm — to form Exonics Therapeutics.

The new company, based in Cambridge, Massachusetts, will use the CRISPR/Cas9 gene-editing technique known as SingleCut with the aim of correcting up to 80 percent of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD).

UT Researcher, With CureDuchenne Support, Launches Company To Treat DMD Using CRISPR/Cas9 Technology